TCB008 for the treatment of COVID-19 [COVID-19]
Research type
Research Study
Full title
A Phase II safety and tolerability, inter-patient pre-defined dose study of ex-vivo expanded allogeneic γδ T-lymphocytes (TCB008) in patients diagnosed with COVID-19.
IRAS ID
296448
Contact name
Louise Devlin
Contact email
Sponsor organisation
TC BioPharm
Eudract number
2021-000742-18
Duration of Study in the UK
1 years, 0 months, 0 days
Research summary
The aim of this clinical study is to evaluate the safety and tolerability of a cell therapy medicinal product called Gamma Delta T Cell Therapy. It is made from a type of white blood cell called T-lymphocytes. A small proportion of T-lymphocytes are gamma delta T-cells (GDT cells). Scientists demonstrated that GDT cells can fight against infections.
Patients may potentially benefit from this treatment that boosts their immune system against the virus and may help to recover faster and not to progress to more severe stage of the COVID-19.The patient involvement is expected to last for just over 1 month. During this time, patients will initially be hospitalised for a minimum of 72 hours and thereafter will have regular health check-ups such as routine blood tests and physical examination.
As with any new treatment, there may be some unwanted side effects. The most common side effects experienced by people who have had GDT cell treatment are flu-like symptoms, such as fever, chills and tiredness. There have been no serious adverse reactions which have been considered to be due to GDT cell therapy.
REC name
London - West London & GTAC Research Ethics Committee
REC reference
21/LO/0389
Date of REC Opinion
1 Jul 2021
REC opinion
Further Information Favourable Opinion